🇺🇸 FDA
Patent

US 10047082

Octahydro fused azadecalin glucocorticoid receptor modulators

granted A61PA61P35/00

Quick answer

US patent 10047082 (Octahydro fused azadecalin glucocorticoid receptor modulators) held by Corcept Therapeutics Incorporated expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P35/00